The use of many halogenated alkanes such as carbon tetrachloride (CCl4), chloroform
(CHCl3) or iodoform (CHI3), has been banned or severely restricted because of their distinct …

Models of liver fibrosis, which include cell culture models, explanted and biopsied human
material, and experimental animal models, have demonstrated that liver fibrosis is a highly …

Inflammasome activation plays a central role in the development of drug‐induced and
obesity‐associated liver disease. However, the sources and mechanisms of inflammasome …

Liver fibrosis and cirrhosis resulting from long-standing liver damage represents a major
health care burden worldwide. To date, there is no anti-fibrogenic agent available, making …

Background & Aims Bone marrow (BM) cells may transdifferentiate into or fuse with organ
parenchymal cells. BM therapy shows promise in murine models of cirrhosis, and clinical …

Background & aims: Myofibroblasts of bone marrow origin have recently been found in a
number of parenchymal organs such as the gut and kidney. We have analyzed the origin of …

Hepatic fibrosis is a wound‐healing response to chronic liver injury, which if persistent leads
to cirrhosis and liver failure. Exciting progress has been made in understanding the …

Fibrogenesis is part of a normal protective response to tissue injury that can become
irreversible and progressive, leading to fatal diseases. Senescent cells are a main driver of …

The renin‐angiotensin system (RAS) is frequently activated in patients with chronic liver
diseases. Angiotensin‐II (AT‐II) has been suggested to play an important role in liver …

Background: It has been shown that expression of the potent angiogenic factor, vascular
endothelial growth factor (VEGF), and its receptors, flt-1 (VEGFR-1) and KDR/Flk-1 (VEGFR …